TOT BIOPHARM International Co. Ltd. (1875) AI Stock Analysis

• Market Cap: HK$1.48B
• Dividend Yield: N/A
• Average Volume (3M): 240.51K
• Price to Earnings (P/E): 181.9
• Beta (1Y): 0.51
• Revenue Growth: 9.41%
• EPS Growth: -32.69%
• Country: HK
• Employees: 611
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 772,787,900
• 10 Day Avg. Volume: 141,880
• 30 Day Avg. Volume: 240,506
• PEG Ratio: -0.18
• Price to Book (P/B): 1.67
• Price to Sales (P/S): 1.11
• P/FCF Ratio: -170.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: HK$2.00 ▲(12.36% Upside)

The overall stock score is primarily influenced by strong financial performance, despite liquidity concerns. Technical analysis indicates bearish momentum, and valuation metrics suggest the stock may be overvalued. The absence of earnings call and corporate events data did not impact the score.

TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model

Company Description

BioDlink International Co., Ltd. is clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. Its product portfolio includes: TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009 and is headquartered in Suzhou, China.

How the Company Makes Money

TOT BIOPHARM generates revenue primarily through the sale of its biopharmaceutical products, which include proprietary drugs and therapies developed in-house. The company has a diverse revenue model that includes direct sales to hospitals and clinics, as well as partnerships with other pharmaceutical companies for co-development and distribution. Additionally, TOT BIOPHARM may earn revenue through licensing agreements, where it licenses its technology or products to other companies for further development or commercialization. Significant partnerships with research institutions and collaborations with global pharmaceutical firms also contribute to the company's earnings, enhancing its market reach and capabilities in product development.

TOT BIOPHARM International Co. Ltd. Financial Statement Overview

Summary

TOT BIOPHARM International Co. Ltd. has shown a strong recovery in revenue and profitability with improved margins and financial health. The balance sheet is solid with low debt levels and positive equity returns. However, liquidity remains a concern due to negative Free Cash Flow, indicating potential cash management challenges.

Income Statement

The company has shown a significant improvement in revenue and profitability. Gross Profit Margin and Net Profit Margin have improved substantially from negative to positive, indicating a turnaround. The EBIT and EBITDA margins have moved from negative to positive, highlighting improved operational efficiency. However, the company faced challenges in previous years with negative growth, which could indicate potential volatility.

Balance Sheet

The balance sheet is strong with a relatively low Debt-to-Equity Ratio, indicating prudent financial leverage. The Return on Equity has turned positive, suggesting effective use of shareholder funds. The Equity Ratio is stable, showing a solid equity base. The company has maintained a healthy cash position over the years, enhancing financial stability.

Cash Flow

The cash flow statements show some concerns. The Free Cash Flow remains negative, impacting the cash flow score. However, the company has improved its Operating Cash Flow to Net Income Ratio, reflecting better cash generation from operations. Continued negative Free Cash Flow indicates potential liquidity challenges, although the company has managed its financing activities to maintain cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07B	1.10B	780.63M	442.18M	76.33M	22.49M
Gross Profit	758.56M	782.43M	573.99M	370.62M	27.47M	15.53M
EBITDA	43.83M	84.96M	10.45M	-5.41M	-224.51M	-254.71M
Net Income	7.26M	34.76M	-37.76M	-49.92M	-261.22M	-288.50M
Balance Sheet
Total Assets	1.48B	1.51B	1.43B	1.26B	710.26M	641.18M
Cash, Cash Equivalents and Short-Term Investments	383.98M	381.26M	351.60M	517.63M	155.38M	225.53M
Total Debt	397.20M	395.47M	345.65M	289.53M	208.56M	7.41M
Total Liabilities	744.74M	779.12M	739.41M	546.59M	375.17M	58.83M
Stockholders Equity	731.68M	729.65M	686.69M	713.88M	335.09M	582.36M
Cash Flow
Free Cash Flow	48.42M	-7.17M	-146.77M	-180.19M	-290.45M	-285.30M
Operating Cash Flow	123.43M	116.40M	56.43M	59.93M	-175.14M	-263.12M
Investing Cash Flow	-80.23M	-122.50M	-164.10M	-282.76M	-108.39M	12.53M
Financing Cash Flow	-7.09M	34.18M	38.23M	481.24M	212.08M	-61.71M

TOT BIOPHARM International Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.06, and below the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 34.13 is Neutral, neither overbought nor oversold. The STOCH value of 6.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1875.

TOT BIOPHARM International Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.48B	181.90	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
6622	47 Neutral	HK$1.72B	-5.70	-14.84%	―	-38.38%	-22.12%
2181	39 Underperform	HK$2.14B	-72.22	-25.72%	―	178.36%	86.74%
6978	37 Underperform	HK$2.16B	-8.13	―	―	―	27.90%
2511	36 Underperform	HK$1.78B	-5.03	-67.27%	―	―	47.42%
2185	32 Underperform	HK$2.02B	-20.86	-14.87%	―	―	22.65%

TOT BIOPHARM International Co. Ltd. Corporate Events

BioDlink Announces Leadership Changes Amidst Resignations

BioDlink International Company Limited announced changes in its leadership, with Dr. Liu and Ms. Yeh-Huang resigning from their respective positions due to family reasons. This reshuffling may impact the company’s strategic direction and governance, as it involves key roles such as the executive director, chief executive officer, and members of the Strategy and ESG Committee.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink International Announces Leadership Restructuring

BioDlink International Company Limited, a Hong Kong-based company, announced significant changes in its leadership structure. Mr. Fu, Shan has been re-designated from a non-executive director to an executive director, continuing his role as chairperson of the Board and various committees. This change positions Mr. Fu to lead and oversee the management and development of the company, potentially impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink International Announces Board and Committee Restructuring

BioDlink International Company Limited, incorporated in Hong Kong, has announced changes to its board of directors and the composition of its board committees. Effective from October 11, 2025, Mr. Fu Shan will serve as the Chairperson of the Strategy and ESG Committee, while Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin will take on various roles across the Audit and Connected Transactions Review, Remuneration, and Nomination Committees. These changes are expected to enhance the governance and strategic oversight of the company.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink Reports Revenue Decline Amidst Global Expansion Efforts

BioDlink International Company Limited reported a 6% decrease in operating revenue for the first half of 2025, attributed to intensified competition and delayed project milestones. Despite a significant 87% drop in net profit, the company expanded its international presence with Bevacizumab injection approvals in Nigeria and Pakistan, and GMP inspections passed in several countries. The company also authorized Zhaoke Ophthalmology Limited as the marketing authorization holder for TAB014 in China, marking a strategic move in the ophthalmic drug market.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink International Schedules Board Meeting for Interim Results

BioDlink International Company Limited has announced that its board of directors will convene on August 12, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

BioDlink International Rebrands with New Name and Identity

BioDlink International Company Limited has officially changed its English name from TOT BIOPHARM International Company Limited, effective July 11, 2025, following shareholder approval. This change is accompanied by amendments to the Articles of Association, a new stock short name ‘BIODLINK-B’ effective July 30, 2025, a new website address, and a new company logo, reflecting the company’s rebranding efforts.

The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.